Previous close | 0.0800 |
Open | 0.0800 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 10.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0800 - 0.0800 |
Contract range | N/A |
Volume | |
Open interest | 187 |
Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 shares of the company on May 20, 2024.
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d